

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Emma Walmsley									
b)	Position/status	Chief Executive Officer									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£12.7500</td><td>1,304</td></tr><tr><td>£12.7500</td><td>1,702</td></tr><tr><td>£12.7500</td><td>1,924</td></tr></table>	Price(s)	Volume(s)	£12.7500	1,304	£12.7500	1,702	£12.7500	1,924	
Price(s)	Volume(s)										
£12.7500	1,304										
£12.7500	1,702										
£12.7500	1,924										
d)	Aggregated information										
	Aggregated volume	4,930									
	Price	£12.7500									
e)	Date of the transaction	2025-04-16									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	854
		£12.7500	734
d)	Aggregated information		
	Aggregated volume	1,588	
	Price	£12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	191
		£12.7500	485
		£12.7500	309

d)	Aggregated information	
	Aggregated volume	985
	Price	£12.7500
e)	Date of the transaction	2025-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	James Ford									
b)	Position/status	SVP and Group General Counsel, Legal and Compliance									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£12.7500</td><td>298</td></tr><tr><td>£12.7500</td><td>491</td></tr><tr><td>£12.7500</td><td>301</td></tr></table>	Price(s)	Volume(s)	£12.7500	298	£12.7500	491	£12.7500	301	
Price(s)	Volume(s)										
£12.7500	298										
£12.7500	491										
£12.7500	301										
d)	Aggregated information										
	Aggregated volume	1,090									
	Price	£12.7500									
e)	Date of the transaction	2025-04-16									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	167
		£12.7500	304
		£12.7500	187
d)	Aggregated information		
	Aggregated volume Price	658 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Luke Miels		
b)	Position/status	Chief Commercial Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£12.7500	458	

		<table><tr><td>£12.7500</td><td>914</td></tr><tr><td>£12.7500</td><td>726</td></tr></table>	£12.7500	914	£12.7500	726
£12.7500	914					
£12.7500	726					
d)	Aggregated information					
	Aggregated volume Price	2,098 £12.7500				
e)	Date of the transaction	2025-04-16				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Shobie Ramakrishnan									
b)	Position/status	Chief Digital and Technology Officer									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044									
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 April 2025 on ADSs held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>33.6000</td><td>134</td></tr><tr><td>33.6000</td><td>222</td></tr><tr><td>33.6000</td><td>143</td></tr></table>	Price(s)	Volume(s)	33.6000	134	33.6000	222	33.6000	143	
Price(s)	Volume(s)										
33.6000	134										
33.6000	222										
33.6000	143										
d)	Aggregated information Aggregated volume Price	499 33.6000									
e)	Date of the transaction	2025-04-16									
f)	Place of the transaction	New York Stock Exchange (XNYS)									

1.	Details of PDMR/person closely associated with them ('PCA')
----	--

a)	Name	David Redfern									
b)	Position/status	President, Corporate Development									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£12.7500</td><td>265</td></tr><tr><td>£12.7500</td><td>581</td></tr><tr><td>£12.7500</td><td>419</td></tr></table>	Price(s)	Volume(s)	£12.7500	265	£12.7500	581	£12.7500	419	
Price(s)	Volume(s)										
£12.7500	265										
£12.7500	581										
£12.7500	419										
d)	Aggregated information										
	Aggregated volume Price	1,265 £12.7500									
e)	Date of the transaction	2025-04-16									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£12.7500	388	
		£12.7500	337	
		£12.7500	700	
d)	Aggregated information			
	Aggregated volume	1,425		
	Price	£12.7500		
e)	Date of the transaction	2025-04-16		
f)	Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	236
		£12.7500	391
		£12.7500	220
d)	Aggregated information		
	Aggregated volume	847	
	Price	£12.7500	
e)	Date of the transaction	2025-04-16	

f)	Place of the transaction	London Stock Exchange (XLON)
----	--------------------------	------------------------------

1.	Details of PDMR/person closely associated with them ('PCA')										
a)	Name	Deborah Waterhouse									
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK									
c)	Initial notification/ amendment	Initial notification									
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a)	Name	GSK plc									
b)	LEI	5493000HZTVUYLO1D793									
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted										
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63									
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan									
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£12.7500</td><td>365</td></tr><tr><td>£12.7500</td><td>537</td></tr><tr><td>£12.7500</td><td>606</td></tr></table>	Price(s)	Volume(s)	£12.7500	365	£12.7500	537	£12.7500	606	
Price(s)	Volume(s)										
£12.7500	365										
£12.7500	537										
£12.7500	606										
d)	Aggregated information	<table><tr><td>Aggregated volume</td><td>1,508</td></tr><tr><td>Price</td><td>£12.7500</td></tr></table>		Aggregated volume	1,508	Price	£12.7500				
Aggregated volume	1,508										
Price	£12.7500										
e)	Date of the transaction	2025-04-16									
f)	Place of the transaction	London Stock Exchange (XLON)									

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	340
		£12.7500	254
		£12.7500	746
d)	Aggregated information		
	Aggregated volume	1,340	
	Price	£12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	11,184.930

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Dr Hal Barron					
b)	Position/status	Non-Executive Director					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044					
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 April 2025					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>35.9948</td><td>3603.574</td></tr></table>	Price(s)	Volume(s)	35.9948	3603.574	
Price(s)	Volume(s)						
35.9948	3603.574						
d)	Aggregated information Aggregated volume Price	N/A (single transaction)					
e)	Date of the transaction	2025-04-15					
f)	Place of the transaction	New York Stock Exchange (XNYS)					

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform,	

	auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 April 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		35.9948	363.602
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-15	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Shobie Ramakrishnan	
b)	Position/status	Chief Digital and Technology Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 April 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		35.9948	437.999
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	

e)	Date of the transaction	2025-04-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFEFDWEISEIL